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Abstract To test the hypothesis on prolonged survival in
glioblastoma cases with increased subventricular zone
(SVZ) radiation dose. Sixty glioblastoma cases were pre-
viously treated with adjuvant radiotherapy and Temozola-
mide. Ipsilateral, contralateral and bilateral SVZs were
contoured and their doses were retrospectively evaluated.
Median follow-up, progression free survival (PFS) and
overall survival (OS) were 24.5, 8.5 and 19.3 months
respectively. Log-rank tests showed a statistically signifi-
cant correlation between contralateral SVZ (cSVZ) dose
[ 59.2 Gy (75th percentile) and poor median PFS (10.37
[95 % CI 8.37–13.53] vs 7.1 [95 % CI 3.5–8.97] months,
p = 0.009). cSVZ dose [ 59.2 Gy was associated with
poor OS in the subgroup with subtotal resection/biopsy
(HR: 4.83 [95 % CI 1.71–13.97], p = 0.004). High ipsi-
lateral SVZ dose of [ 62.25 Gy (75th percentile) was
associated with poor PFS in both subgroups of high
performance status (HR: 2.58 [95 % CI 1.03–6.05],
p = 0.044) and SVZ without tumoral contact (HR: 10.57
[95 % CI 2.04–49], p = 0.008). The effect of high cSVZ
dose on PFS lost its statistical significance in multivariate
Cox regression analysis. We report contradictory results
compared to previous publications. Changing the clinical
practice based on retrospective studies which even do not
indicate consistent results among each other will be dan-
gerous. We need carefully designed prospective random-
ized studies to evaluate any impact of radiation to SVZ in
glioblastoma.
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Introduction
Despite modern treatment modalities, outcome of glio-
blastoma is still poor. Median survival is around 14 months
[1, 2]. Standard primary treatment of glioblastoma is sur-
gical resection followed by chemo-radiotherapy and adju-
vant chemotherapy with six cycles of Temozolamide [3].
Local recurrence is the main problem during the course of
the disease [4].
Neural stem cells are located in the subventricular zone
(SVZ) [5]. A growing body of evidence indicates cells with
cancer stem cell (CSC) properties causing glioblastoma in
preclinical models [6–9]. CSCs are known to be resistant to
radiation and chemotherapy [10–12]. Conversely, there are
also publications demonstrating that cells residing in SVZ
have no proliferative or triggering effect on tumor. More-
over, there is evidence of antitumoral immune-reactive and
inflammatory response orginated from the neural stem cells
in the SVZ [13, 14] against malignancy.
Lim et al. [15] and Adeberg et al. [16] separated glio-
blastoma cases into categories based on relationship of
tumor location to SVZ and/or cortex, reporting that CSCs
residing in SVZ may be responsible of glioblastoma
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formation in some cases. Calabrese et al. [17] showed that
cells having CSC properties can be ectopically located in
any region of the brain where vascular endothelia is present
regardless of SVZ. An elegant review describes the
advancements of CSC research and the lack of consensus
about ‘Glioblastome CSCs’ [18].
There are four retrospective studies which reported
better outcomes with higher ipsilateral SVZ (iSVZ) radia-
tion doses for either overall survival (OS), progression free
survival (PFS) or both [19–22], but without any dose
consensus. We could only find one abstract with negative
results showing no association between iSVZ dose and
survival [23]. We doubted whether this situation is related
to a publication bias against negative results and whether
we can obtain similar results showing any statistical cor-
relation or not, hence the latter becoming the aim of this
study.
Materials and methods
Sixty-six patients with newly diagnosed glioblastoma were
treated in our clinic between January 2010 and June 2012.
Patients had to be over 18 years old with histopathologi-
cally confirmed glioblastoma having at least 1 month of
follow-up after the end of concomitant chemo-radiother-
apy. Patients who were not treated with standard chemo-
radiotherapy [3] were excluded. Discontinuation of radio-
therapy or chemotherapy during the concomitant phase (2
cases) was also an exclusion criterion. In order to have a
minimal follow-up of one year, patients whose treatments
were ended within the last year before the data analysis
were not included in the study. Pre- and post-operative
Magnetic Resonance Imaging (MRI) was mandatory.
Patients with multiple tumors, bilaterally extending tumors
(2 cases), tumors arising from the midline (1 case) or from
an infratentorial location (1 case) were excluded. The
remaining 60 patients were included in the study.
Treatment planning system used before 2010 was
unavailable. Therefore the backed-up data of 3D conformal
radiotherapy plans (3DCRT) before 2010 could not be
acquired. Planning tomographies were scanned with
2.5 mm slice thickness. CTV was defined as resection
cavity and residual tumor (if any) identified on gadolinium
enhanced T1 sequence plus a margin of 2 cm including
edema visualized in T2 sequence of MRIs, but at the same
time excluding anatomical barriers. PTV margin was 3 mm
around CTV. 60 Gy in 2 Gy daily fractions was prescribed
to PTV in single phased 3DCRT plans. Treatments of two
patients were planned in Varian Eclipse (Varian Medical
Systems, Palo Alto, CA, USA) and the rest in Precise Plan
(version 2.16 – Elekta Oncology Systems, Crawley, UK)
software, both configured for 6-MV photons.
SVZ volume delineation was done by a single physician
according to guidelines [19]. Structures of 3–5 mm thick
strips were created lateral to the lateral ventricles. Ipsilat-
eral SVZ were defined as the SVZ on the tumor side. For
each patient, contralateral and bilateral SVZ were also
created (cSVZ and bSVZ respectively). Dose to each SVZ
volume was calculated and measured with dose volume
histograms generated on the original plans retrospectively.
All patients were evaluated three monthly after the end of
the adjuvant chemotherapy. Progression was defined as
radiological verification of recurrence or progression. Addi-
tional MRIs were requested in case of clinical suspicion.
Patients in undistinguished progression/pseudoprogression
status were continued to be followed and confirmed pro-
gressions were retrospectively registered with their initial
date of suspicion as the date of progression. Decision for
salvage treatment depended on mutual discretion of the
treating physician, patient and the family.
Information about patients lost to follow-up was
acquired from the national database. Descriptive statistics
were reported. Date of surgery or biopsy (Bx) was chosen
for PFS and OS calculation. Kaplan–Meier method with
95 % confidence intervals (CI) was used for median PFS
and OS calculation. Patients lost to follow-up or those who
were alive without progression were censored at the time of
last follow-up for PFS. Patients who were alive were
censored at the time of analysis for OS. CTV, iSVZ, cSVZ
and bSVZ doses and CTV volumes were dichotomized
each for 25th, 50th (median) and 75th percentiles. Log-
rank tests for PFS and OS were used for SVZ infiltration
(?/-), median age (C54; ?/-), Karnofsky Performance
Status (KPS C 90; ?/-), gender (m/f), gross total resec-
tion status (GTR; ?/-), doses to CTV, CTV volumes and
doses to SVZ structures. Univariate and multivariate Cox
proportional hazard models were used to determine the
prognostic factors and investigate any relationship between
the parameters and survival. Spearman correlation coeffi-
cient was used to study the relationship between CTV
volume and dose to SVZ’s.
All tests were done using JMP 9.0 (SAS Institute Inc.
North Carolina, USA). Two-sided p values under 0.05 were
considered as statistically significant.
Results
Descriptive patient characteristics are available on Table 1.
All patients had newly diagnosed glioblastomas. Median
follow-up for surviving patients were 24.5 months. Median
PFS and OS of the whole cohort were 9.5 (95 % CI
7.7–11.1) and 19.27 (95 % CI 12.77–25.23) months
respectively. All patients completed concomitant chemo-
radiation course without any interruption.
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Log-rank tests showed a significant relation of cSVZ dose
[59.2 Gy (75th percentile) with poor median PFS (10.37
[95 % CI 8.37–13.53] vs 7.1 [95 % CI 3.5–8.97] months,
p = 0.009) (Fig. 1). PFS were also worse in women than
men (median PFS of 7.68 [95 % CI 4–9] vs 10.77 [95 % CI
8.57–23.2] months, p = 0.009). Those two parameters had
significant effect on PFS in univariate Cox proportional
hazard analysis, but the effect of high cSVZ dose on PFS
lost its statistical significance in multivariate analysis
(Table 2) and only sex remained as a significant factor.
Univariate analyses on doses were repeated by stratify-
ing the patients into subgroups of age, sex, resection status,
SVZ tumoral contact and KPS (Table 3). cSVZ[ 59.2 Gy
remained to be a significant prognostic factor for poor PFS
in subgroups of age C 54 (HR: 6.78 [95 % CI 1.97–24.26],
p = 0.003), male gender (HR: 3.96 [95 % CI 1.36–10.33],
p = 0.014), subtotal resection STR/Bx (HR: 8.9 [95 % CI
2.83–30.9], p = 0.001), SVZ contact positive (HR: 2.56
[95 % CI 1.05–6.19], p = 0.039) and KPS C 90 (HR: 3.43
[95 % CI 1.09–9.25], p = 0.037). cSVZ dose [ 59.2 Gy
was also associated with poor OS in STR/Bx subgroup
(HR: 4.83 [95 % CI 1.71–13.97], p = 0.004). High iSVZ
dose of [62.25 Gy (75th percentile) was associated with
poor PFS in both subgroups of high performance status
(HR: 2.58 [95 % CI 1.03–6.05], p = 0.044) (Fig. 2) and
SVZ without tumoral contact (HR: 10.57 [95 % CI
2.04–49], p = 0.008) (Fig. 3).
Finally we used Spearman’s q to identify any correlation
between CTV volume and SVZ doses. Although CTV
volume was associated with neither PFS nor OS in uni-
variate and multivariate analysis, CTV volume was sig-
nificantly associated with each SVZ dose (q range
0.39–0.61, p \ 0.002).
Discussion
Even today glioblastoma is a devastating disease with poor
survival rates and causing gradually deteriorating quality of
life. Our patient characteristics and methodology was quite
Table 1 Description of patient and treatment characteristics
Characteristic All (n = 60)
Age at diagnosis (years)
Mean 53.1 ± 12.7
Median 54 (range 24–86)
Sex
Female 21 (35 %)
Male 39 (65 %)
Extent of resection
GTR 26 (43.3 %)
STR/Bx 34 (56.7 %)
KPS
C90 33 (55 %)
\90 27 (45 %)
Tumor SVZ contact
? 32 (53.3 %)
– 28 (46.7 %)
Tumor side
Left 27 (45 %)
Right 33 (55 %)
Lobe where the tumor resides
Frontal 12 (20 %)
Parietal 5 (8.3 %)
Temporal 19 (31.7 %)
Occipital 4 (6.7 %)
Intraventricular 1 (1.6 %)
Multilobar extension 19 (31.7 %)
CTV
Mean volume (cm3) 299 ± 158.5
Quartile volumes (25th, 50th, 75th) 174.1, 280.9, 400.2
Mean dose (Gy) 62.7 ± 0.7
Quartile doses (25th, 50th, 75th) 62.1, 62.7, 63.2
iSVZ
Mean volume (cm3) 5.2 ± 2.4
Mean dose (Gy) 58.8 ± 6.5
Quartile doses (25th, 50th, 75th) 58.3, 61.4, 62.2
cSVZ
Mean volume (cm3) 6.4 ± 2.3
Mean dose (Gy) 44.9 ± 15.9
Quartile doses (25th, 50th, 75th) 32.3, 50.6, 59.2
bSVZ
Mean volume (cm3) 11.6 ± 4.2
Mean dose (Gy) 51.9 ± 10.4
Quartile doses (25th, 50th, 75th) 43.8, 55, 60.4
Fig. 1 Progression free survival by contralateral subventricular zone
(cSVZ) dose based on log-rank test
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similar with the previous studies [19–22] about this sub-
ject: Male/female ratio seems to be around 2:1 [19–22]; the
GTR rates [21, 22], performance scores [22] and periven-
tricular tumoral contact ratios [22] are also nearly the same.
But most of the dosimetric data and their correlation to
outcome do not comply with previously published data.
Mean doses to iSVZ, cSVZ and bSVZ are very heteroge-
neous throughout the published literature. Our dosimetric
results are only concordant with those of Gupta et al. [20].
The reason for that might be the difference in techniques or
another factor, like tumor location. For example, only Lee
et al. [21] did not include patients with multiple and
bilateral tumors. Others did not report about this entity or
included [20] those patients. Only Chen et al. [22] reported
their choice of planning method which was intensity
modulated radiotherapy. We do not have information about
the technique used by other groups. Total prescribed doses
also varied with the greatest range of 30–63 Gy in the
study of Evers et al. [19] who also included grade 3 glial
tumors. Target volume definition strategy and 60 Gy single
phase approach [3] we and Gupta et al. used is widely
preferred in European centers whereas two phase approach
which is preferred in North America was chosen in the
studies of Chen et al. and Lee et al.
The first study including only glioblastoma patients was
published as an abstract by Slotman et al. [23] with a
cohort of 40 patients. So far it is the only negative study we
are aware of. The second study was published by Gupta
et al. [20]. They studied 40 glioblastoma cases. Old age
([50), poor recursive partitioning analysis class and
increased cSVZ dose were related significantly to worse
PFS and OS in univariate survival analysis. In multivariate
Cox model, only iSVZ dose was significant for OS. Results
being different from the present study may be related to
three factors: First, multifocal and bilateral tumors were
also included in the study. Second, there is no information
Table 2 Treatment outcome
analysis of glioblastoma
patients with Cox proportional
hazards model




HR (95 % CI) p value HR (95 % CI) p value
Univariate analysis
Age C 54 vs \ 54 1.44 (0.79–2.66) 0.238 1.63 (0.87–3.16) 0.131
Sex (f vs m) 2.83 (1.48–5.36) 0.002 1.44 (0.74–2.71) 0.274
GTR vs STR/Bx 1.47 (0.77–2.80) 0.240 1.10 (0.55–2.19) 0.785
Tumor contacts SVZ 1.13 (0.62–2.06) 0.700 1.24 (066–2.37) 0.509
KPS C 90 1.04 (0.58–1.92) 0.888 1.17 (0.62–2.27) 0.621
CTV volumes (cm3)
[174.1 0.74 (0.38–1.53) 0.408 0.83 (0.41–1.87) 0.638
[280.9 1.15 (0.63–2.09) 0.638 1.35 (0.72–2.61) 0.352
[400.2 0.89 (0.43–1.72) 0.736 0.82 (0.38–1.63) 0.580
CTV doses (Gy)
[62.1 0.86 (0.46–1.73) 0.665 0.93 (0.47–1.97) 0.845
[62.7 0.84 (0.46–1.53) 0.578 0.91 (0.48–1.72) 0.769
[63.2 0.94 (0.46–1.79) 0.848 0.62 (0.28–1.27) 0.197
iSVZ doses (Gy)
[58.3 1.43 (0.72–3.08 0.318 1.12 (0.54–2.62) 0.773
[61.4 1.09 (0.60–1.99) 0.767 0.84 (0.44–1.59) 0.591
[62.2 1.16 (0.56–2.24) 0.671 1.10 (0.52–2.14) 0.800
cSVZ doses (Gy)
[32.3 1.04 (0.55–2.12) 0.906 1.74 (0.78–4.61) 0.187
[50.6 0.98 (0.54–1.78) 0.946 1.11 (0.59–2.13) 0.744
[59.2 2.42 (1.18–4.71) 0.018 1.49 (0.72–2.88) 0.268
bSVZ doses (Gy)
[43.8 0.84 (0.43–1.78) 0.640 1.18 (0.55–2.93) 0.689
[55 1.02 (0.56–1.87) 0.947 1.19 (0.62–2.30) 0.604
[60.4 0.97 (0.46–1.89) 0.938 0.67 (0.29–1.37) 0.282
Multivariate Cox regressiona
Sex (f vs m) 2.39 (1.19–4.73) 0.015 – –
cSVZ [ 59.2 Gy 1.72 (0.80–3.53) 0.161 – –
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about associated parameters in the multivariate Cox model
being used as nested or not. Third; different from the
present study, censored patients had to be with at least
6-months of follow-up after completion of therapy.
The last two studies were published recently. Lee et al.
[21] analysed a combined cohort of 173 patients from two
centers. This is the largest cohort studied thus far. Twenty-
one patients received iSVZ dose[ 59.4 Gy and univariate
analysis showed a significantly longer median PFS with
high dose. Surgery (STR vs GTR and Bx vs GTR), age[50
and occipital lobe tumor location were also significantly
associated with both PFS and OS in the univariate analysis.
In one of the two multivariate Cox models used, iSVZ dose
[ 59.4 Gy, surgery (GTR vs STR and GTR vs Bx) and age
\50 remained to be significantly associated with better
PFS but only surgery was correlated with better OS. This
article has some unique features: This is the only study
which also reported the anatomical sites of the tumors. On
the other hand, the authors hypothesized at the beginning
that 59.4 Gy may be effective to control CSCs, because
59.4–60 Gy is prescribed in glioblastoma as a standard,
therefore used this dose threshold in the statistical analysis
and the results were supporting the hypothesis. But when
they redid the calculation with other arbitrary threshold
levels and mean dose ([50 Gy) to iSVZ, none were asso-
ciated with significant improvement in PFS. A similar issue
is valid for the arbitrary selection of age (50). It is neither
mean, median nor some other percentile value. Addition-
ally, our concern for statistics regarding the use of asso-
ciated values in the same multivariate Cox model in the
study of Gupta et al. repeats itself here.
Table 3 Univariate subgroup
analyses with Cox proportional
hazard model (only significant
results shown)
– Non-significant (p [ 0.05)
Dose stratified under subgroups PFS OS
HR (95 % CI) p value HR (95 % CI) p value
Age C 54
cSVZ [ 59.2 Gy 6.78 (1.97–24.26) 0.003 – –
Male sex
cSVZ [ 59.2 Gy 3.96 (1.36–10.33) 0.014 – –
STR/Bx
cSVZ [ 59.2 Gy 8.9 (2.83–30.9) 0.001 4.83 (1.71–13.97) 0.004
SVZ contact: yes
cSVZ [ 59.2 Gy 2.56 (1.05–6.19) 0.039 – –
SVZ contact: no
iSVZ [ 62.2 Gy 10.57 (2.04–49) 0.008 – –
KPS C 90
iSVZ [ 62.2 Gy 2.58 (1.03–6.05) 0.044 – –
cSVZ [ 59.2 Gy 3.43 (1.09–9.25) 0.037 – –
Fig. 2 Progression free survival by ipsilateral subventricular zone
(iSVZ) dose in patients having Karnofsky Performance C90 based on
log-rank test
Fig. 3 Progression free survival by ipsilateral subventricular zone
dose (iSVZ) in patients having no tumor contact to the subventricular
zone based on log-rank test
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Chen et al. [22] retrospectively analyzed a set of 116
cases. Minimum follow-up time was 7 months. It is the first
and only study reporting the planning technique and the
presence of direct tumoral contact to SVZ which was not
prognostic. In the univariate analysis, only craniotomy vs
biopsy was associated with better PFS. For OS age \70
was a better prognostic factor in the subgroups of GTR and
STR patients. The subgroup of GTR patients who received
[40 Gy had significantly improved PFS and OS in the
multivariate analysis. But the reason for choosing 40 Gy as
a threshold was not stated in the article.
In our univariate analysis increased cSVZ [59.2 Gy
was a strong predictor of PFS and remained to be a sig-
nificant factor throughout the subgroups of KPS C 90, age
C54, male sex, non-GTR and patients with tumoral con-
tact to SVZ. It was a significant factor for worse OS in
subgroup without GTR too. Probably the association
between increased cSVZ dose and worse PFS is indirectly
associated with the extent of disease burden through large
CTV volumes. We could not show any significant asso-
ciation between CTV properties and survival but found a
significant correlation between CTV volume and SVZ
doses. But the same logic should apply to iSVZ dose
however mostly it did not: We could only observe a
significant impact of increased iSVZ dose [62.25 Gy on
worse OS in subgroups of KPS C90 and patients who did
not have any tumor close to ventricles. Finally in the
multivariate analysis, only sex remained to be a signifi-
cant factor on PFS. On the other hand, there is also pre-
clinical evidence about anti-tumoral activity and immune
response of stem cells residing in the SVZ against glial
malignancies [14]. One can even hypothesize that
increased radiation dose destroys stem cells residing in
SVZ, which involve in parenchymal repair and generate
an immune response against tumor.
Our study has limitations: It has all major drawbacks of
a retrospective study with a small sample size. Besides we
did not investigate the O6-methylguanine-methyltransfer-
ase promoter status which may have changed the results.
We did not have any distant recurrences or metachronous
primaries and therefore could not analyze its relationship
with SVZ parameters if there is any.
Relationship between glioblastoma location, SVZ and
dose to CTV and SVZs is a very questionable issue prone
to speculative discussion. As we tried to emphasize before,
those parameters are somehow connected to each other and
therefore susceptible to analytical errors. In a disease with
such a poor outcome it is exciting to see data about
increasing survival rates just by increased radiation dose.
But changing the clinical practice based on retrospective
studies which even do not indicate consistent results among
each other will be dangerous. However it is definitely a
subject worth exploring. We need carefully designed
prospective randomized studies to evaluate any impact of
radiation to SVZ in glioblastoma.
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